According to these data, a therapeutic strategy for type II diabetes, metabolic syndrome and cardiovascular disease may include the up-regulation of plasma adiponectin, the up-regulation of adiponectin receptors or the development of ADIPORs agonists able to stimulate adiponectin receptors [39]. The gene discussed is ADIPOQ; the disease is type 2 diabetes mellitus.